July 18th 2024
Patrick Boland, MD, discussed the practice-changing implications of the phase 3 ESOPEC study comparing FLOT vs CROSS regimens for the treatment of esophageal adenocarcinoma.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
DeFianCe Study of DKN-01/Bevacizumab/Chemo Enrolls First Patient With Colorectal Cancer
October 19th 2022The phase 2 DeFianCe study will evaluate the safety and efficacy of DKN-01 combined with bevacizumab and chemotherapy in patients with colorectal cancer vs becazixumab and chemotherapy alone.
Read More
Study of Onvansertib Plus SOC in Metastatic Colorectal Cancer Enters Phase 2
September 19th 2022Following reports of durable response in a phase 1 study, the combination of onvansertib FOLFIRI, and bevacizumab will be evaluating in a phase 2 study of patients with metastatic colorectal cancer.
Read More
RLY-4008 Shows DCR of 100% in FGFR+ Cholangiocarcinoma
September 11th 2022A novel FGFR inhibitor, RLY-4008, induced high response rates and encouraging durability in patients with FGFR inhibitor–naïve cholangiocarcinoma harboring an FGFR2 fusion or rearrangement, according to data from the phase 1/2 ReFocus trial presented at the 2022 ESMO Congress.
Read More
ISGIO® Seeks to Clarify Gastrointestinal Cancer Updates for the Clinic
August 31st 2022During the Annual Meeting of the International Society of Gastrointestinal Oncology, experts in the field and investigators from pivotal studies will elucidate how these advances can be used to guide treatment, and how to choose between available treatments in specific patient populations.
Read More
Durvalumab Triplet Improves OS Across Biliary Tract Cancer Locations
August 23rd 2022In findings presented at the ESMO World Congress on Gastrointestinal Cancer 2022, patients with intrahepatic and extrahepatic cholangiocarcinoma who were treated with the durvalumab triplet regimen demonstrated improved overall survival compared with the chemotherapy doublet.
Read More
Frontline Therapy Shows 3-Fold OS Improvement vs BSC in Unresectable Advanced or Metastastic ESCC
August 11th 2022Earlier treatment in patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma may offer better survival benefit compared with chemotherapy or best supportive care.
Read More
LYNK-003 Trial of Olaparib in Metastatic Colorectal Cancer Halted Due to Futility
August 4th 2022The LYNK-003 trial evaluating olaparib monotherapy or in combination with bevacizumab in patients with unresectable or metastatic colorectal cancer who have not progressed following first-line induction has ended due to futility.
Read More
ctDNA Informs Adjuvant Chemotherapy Decision in Patients With Stage II Colon Cancer
July 15th 2022In an interview with Targeted Oncology, Cristian Tomasetti, PhD, discussed the role of circulating tumor DNA in understanding the need for adjuvant chemotherapy in patients with stage II colon cancer. He explained how circulating tumor DNA can signal a patient’s risk of disease recurrence after surgery.
Read More